Keep a close eye on The Walt Disney Company (DIS). It delivered strong financial results, highlighted by an increase of 23% year-over-year in diluted earnings per share (EPS) driven by record revenue as well as significant growth in segment operating income
For its first quarter fiscal 2015, DIS posted revenues of $13.39 billion, a 9% increase year over year, non-GAAP segment operating income of $3.55 billion, a 17% increase compared to the same period the prior year, and adjusted net income of $2.18 billion, or diluted EPS of $1.27, versus adjusted net income of $1.84 billion, or diluted EPS of $1.03 in the first quarter fiscal 2014, these results better than the Capital IQ Consensus Estimate of $1.07 earnings per share on revenues of $12.88 billion
DIS said these results reflect the strength of its brands and high quality content and demonstrate that the company's proven franchise strategy creates long-term value across all of its businesses
DIS, together with its subsidiaries and affiliates, is a leading diversified international family entertainment and media enterprise with five business segments: media networks, parks and resorts, studio entertainment, consumer products and interactive media
More abut The Walt Disney Company (DIS) at www.thewaltdisneycompany.com
**
Breast cancer in women is the second most common type of cancer in the United States. It forms in the breast tissue and in advanced cases, spreads to surrounding normal tissue. The National Cancer Institute estimates that 232,670 American women were diagnosed with breast cancer and 40,000 died from the disease in 2014.
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Pfizer Inc.'s (PFE) Ibrance (palbociclib) in combination with letrozole, for the treatment of postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced breast cancer as initial endocrine-based therapy for their metastatic disease.
The drug’s efficacy was demonstrated in 165 postmenopausal women with ER-positive, HER2-negative advanced breast cancer who had not received previous treatment for advanced disease. Clinical study participants were randomly assigned to receive PFE's Ibrance in combination with letrozole or letrozole alone. Participants treated with Ibrance plus letrozole lived about 20.2 months without their disease progressing (progression-free survival), compared to about 10.2 months seen in participants receiving only letrozole.
PFE's Ibrance(R) is being approved under the FDA’s accelerated approval program, which allows approval of a drug to treat a serious or life-threatening disease based on clinical data showing the drug has an effect on a surrogate endpoint reasonably likely to predict clinical benefit to patients. This program provides earlier patient access to promising new drugs while the company conducts confirmatory clinical trials
PFE's Ibrance works by inhibiting molecules, known as cyclin-dependent kinases (CDKs) 4 and 6, involved in promoting the growth of cancer cells.
PFE would price Ibrance at $9,850 a month, or $118,200 per year. The company said in a statement that price is not the cost that most patients or payors pay.
PFE's Ibrance (palbociclib) is available to order immediately through select specialty pharmacies
PFE, a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide. Its product portfolio includes medicines and vaccines, as well as various consumer healthcare products
More about Pfizer Inc. (PFE) at www.Pfizer.com
**
Crown Equity Holdings Inc. (CRWE) provides marketing solutions that boost customer awareness and merchant visibility on the Internet. The company is currently developing its CRWE Network ( www.CRWE-PR.com ), a growing network of community targeted sites.
It has recently included the City of Santa Clara, CA ( www.santaclara.crwe-pr.com ) into the CRWE Network.
Santa Clara is located in Santa Clara County, California, in the center of the Silicon Valley, northwest of San Jose and 45 miles (72 km) southeast of San Francisco. From historic homes to high tech industry and theme park thrill rides, the City of Santa Clara has it all.
The City of Santa Clara had an estimated population in 2013 (U.S. Census Bureau) of 120,245, and represents an important marketplace for the CRWE Network, which business model is based on selling advertising to businesses targeting both locally and nationally
The CRWE Network has reached the 1487th community website in the U.S. and includes coverage in the states of California, Mississippi, Michigan, Florida, Nevada and New York, as well as across 10 provinces in Canada.
The company’s CRWE Press Release ( www.crwepressrelease.com ) offers increased visibility with cost effective solutions through the distribution of information to the entire CRWE Network for both public and private companies.
More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com
**
Disclaimer: CRWE-PR Finance is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at CRWE-PR Finance www.finance.crwe-pr.com/disclaimer
For its first quarter fiscal 2015, DIS posted revenues of $13.39 billion, a 9% increase year over year, non-GAAP segment operating income of $3.55 billion, a 17% increase compared to the same period the prior year, and adjusted net income of $2.18 billion, or diluted EPS of $1.27, versus adjusted net income of $1.84 billion, or diluted EPS of $1.03 in the first quarter fiscal 2014, these results better than the Capital IQ Consensus Estimate of $1.07 earnings per share on revenues of $12.88 billion
DIS said these results reflect the strength of its brands and high quality content and demonstrate that the company's proven franchise strategy creates long-term value across all of its businesses
DIS, together with its subsidiaries and affiliates, is a leading diversified international family entertainment and media enterprise with five business segments: media networks, parks and resorts, studio entertainment, consumer products and interactive media
More abut The Walt Disney Company (DIS) at www.thewaltdisneycompany.com
**
Breast cancer in women is the second most common type of cancer in the United States. It forms in the breast tissue and in advanced cases, spreads to surrounding normal tissue. The National Cancer Institute estimates that 232,670 American women were diagnosed with breast cancer and 40,000 died from the disease in 2014.
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Pfizer Inc.'s (PFE) Ibrance (palbociclib) in combination with letrozole, for the treatment of postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced breast cancer as initial endocrine-based therapy for their metastatic disease.
The drug’s efficacy was demonstrated in 165 postmenopausal women with ER-positive, HER2-negative advanced breast cancer who had not received previous treatment for advanced disease. Clinical study participants were randomly assigned to receive PFE's Ibrance in combination with letrozole or letrozole alone. Participants treated with Ibrance plus letrozole lived about 20.2 months without their disease progressing (progression-free survival), compared to about 10.2 months seen in participants receiving only letrozole.
PFE's Ibrance(R) is being approved under the FDA’s accelerated approval program, which allows approval of a drug to treat a serious or life-threatening disease based on clinical data showing the drug has an effect on a surrogate endpoint reasonably likely to predict clinical benefit to patients. This program provides earlier patient access to promising new drugs while the company conducts confirmatory clinical trials
PFE's Ibrance works by inhibiting molecules, known as cyclin-dependent kinases (CDKs) 4 and 6, involved in promoting the growth of cancer cells.
PFE would price Ibrance at $9,850 a month, or $118,200 per year. The company said in a statement that price is not the cost that most patients or payors pay.
PFE's Ibrance (palbociclib) is available to order immediately through select specialty pharmacies
PFE, a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide. Its product portfolio includes medicines and vaccines, as well as various consumer healthcare products
More about Pfizer Inc. (PFE) at www.Pfizer.com
**
Crown Equity Holdings Inc. (CRWE) provides marketing solutions that boost customer awareness and merchant visibility on the Internet. The company is currently developing its CRWE Network ( www.CRWE-PR.com ), a growing network of community targeted sites.
It has recently included the City of Santa Clara, CA ( www.santaclara.crwe-pr.com ) into the CRWE Network.
Santa Clara is located in Santa Clara County, California, in the center of the Silicon Valley, northwest of San Jose and 45 miles (72 km) southeast of San Francisco. From historic homes to high tech industry and theme park thrill rides, the City of Santa Clara has it all.
The City of Santa Clara had an estimated population in 2013 (U.S. Census Bureau) of 120,245, and represents an important marketplace for the CRWE Network, which business model is based on selling advertising to businesses targeting both locally and nationally
The CRWE Network has reached the 1487th community website in the U.S. and includes coverage in the states of California, Mississippi, Michigan, Florida, Nevada and New York, as well as across 10 provinces in Canada.
The company’s CRWE Press Release ( www.crwepressrelease.com ) offers increased visibility with cost effective solutions through the distribution of information to the entire CRWE Network for both public and private companies.
More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com
**
Disclaimer: CRWE-PR Finance is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at CRWE-PR Finance www.finance.crwe-pr.com/disclaimer
